Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner
Vladimir G. Gainullin, … , Cynthia J. Hommerding, Peter C. Harris
Vladimir G. Gainullin, … , Cynthia J. Hommerding, Peter C. Harris
Published January 9, 2015
Citation Information: J Clin Invest. 2015;125(2):607-620. https://doi.org/10.1172/JCI76972.
View: Text | PDF
Research Article Article has an altmetric score of 9

Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner

  • Text
  • PDF
Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited nephropathy responsible for 4%–10% of end-stage renal disease cases. Mutations in the genes encoding polycystin-1 (PC1, PKD1) or polycystin-2 (PC2, PKD2) cause ADPKD, and PKD1 mutations are associated with more severe renal disease. PC1 has been shown to form a complex with PC2, and the severity of PKD1-mediated disease is associated with the level of the mature PC1 glycoform. Here, we demonstrated that PC1 and PC2 first interact in the ER before PC1 cleavage at the GPS/GAIN site and determined that PC2 acts as an essential chaperone for PC1 maturation and surface localization. The chaperone function of PC2 was dependent on the presence of the distal coiled-coil domain and was disrupted by pathogenic missense mutations. In Pkd2–/– mice, complete loss of PC2 prevented PC1 maturation. In Pkd2 heterozygotes, the 50% PC2 reduction resulted in a nonequimolar reduction (20%–25%) of the mature PC1 glycoform. Interbreeding between various Pkd1 and Pkd2 models revealed that animals with reduced levels of functional PC1 and PC2 in the kidney exhibited severe, rapidly progressive disease, illustrating the importance of complexing of these proteins for function. Our results indicate that PC2 regulates PC1 maturation; therefore, mature PC1 levels are a determinant of disease severity in PKD2 as well as PKD1.

Authors

Vladimir G. Gainullin, Katharina Hopp, Christopher J. Ward, Cynthia J. Hommerding, Peter C. Harris

×

Figure 5

Maturation of PC1 is associated with the dosage of PC2.

Options: View larger image (or click on image) Download as PowerPoint
Maturation of PC1 is associated with the dosage of PC2.
(A) Membrane pro...
(A) Membrane protein purified from P9 mouse kidneys of WT, Pkd2+/–, Pkd1+/–, and bigenic combinations with the Pkd1RC/RC genotype and Pkd2WS25 allele assayed by SDS-PAGE and probed with PC1 NT and PC2 antibodies. Densitometric profiles of the NT products are shown with a Coomassie-stained loading control. Reduction of Pkd2 reduced the level of PC1-NTR, while Pkd1 reduction lowered the level of both products. Note in Pkd1RC/RC animals that the PC1-FL product is more evident, consistent with the previously described partial cleavage defect (20). Representative blots are shown from 3 independent experiments. (B) IB of membrane-purified protein from WT, Pkd1RC/RC Pkd2+/+, and Pkd1RC/RC Pkd2+/– MEFs detected with PC1 NT or PC2 antibodies showing the PC1-FL, PC1-NTR, and PC1-NTS glycoforms, PC2, and control Coomassie band. Representative blots are shown from 3 independent experiments. (C) Quantification of PC1-NTR from MEFs with various Pkd1 and Pkd2 genotypes. Results were derived from a minimum of 3 independent IBs and biological replicates obtained from 2 separate crosses (numbers [n] indicated) and compared with the WT average from each group, with significance determined by the Student’s t test. (D) Relative ratio of PC1-NTR to NTS expression for indicated MEF genotypes (numbers [n] indicated). The significance of the difference between means was compared using the Student’s t test. For C and D, quartile box plots represent the median, quartiles, and minimum/maximum range, with means of each group in parentheses. **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 3 X users
Referenced in 3 patents
Highlighted by 1 platforms
95 readers on Mendeley
See more details